1. Suggestions in the Integrative Tumor Board should not be construed as recommendations for medical treatment. If a patient reading this material is interested in implementing suggestions made in this feature, he or she should discuss them with a physician and other experienced health professionals familiar with his or her medical history. Appearance of various suggestions for intervention in Integrative Tumor Board articles should not be construed as endorsements of these interventions by the journal's editorial staff or members of any of its editorial boards. Specific problem areas in Tumor Board suggestions will be noted in the Integrative Physician's Perspective, especially in areas that might pose potential risks; we will not, however, discuss every area. 2. Recommendations in the Tumor Board are not presented as an example of how patients should be treated from an integrative medicine perspective. Actual treatment at an integrative clinic requires regular interaction and exchange among the cooperating practitioners and overall supervision by a physician who is aware of the potential contributions of various disciplines.
Not all of the suggestions made in Integrative Tumor
Board articles will be solidly evidence based, particularly since some aspects of integrative care fall into the category of intangibles. Still, we are encouraging integrative practitioners to make an attempt to anchor suggestions in scientific evidence, or at least to submit suggestions that are not unreasonable from a scientific or psychological viewpoint, or from a traditional medicine perspective in the articles submitted by practitioners from various schools of traditional medicine. 4. We expect that the many evidence-based or scientifically reasonable suggestions in Integrative Tumor Board articles will be viewed with seriousness even by readers accustomed to working in a conventional medicine perspective. Conventionally oriented health professionals should realize that their cancer patients may indeed be seeing practitioners who work from less evidence-based perspectives. We strongly feel both that this is a relevant aspect of integrative care and that it is important that health professionals understand the nature of such perspectives and some practices they prescribe.
5. The information given to contributing practitioners is in general the clinical data obtained before counseling the patient on an integrative intervention. Laboratory analyses and some traditional medicine diagnostic techniques may be absent from the presentation. Practitioners may make their own recommendations for laboratory analyses and other diagnostic techniques.
Breast Cancer

Case Presentation
Presenting complaint: Female, 51 years old, with stage-IV lobular carcinoma of the breast with metastases identified to the skeleton.
History of present illness:
The patient's history dates back to July of 1995 when she felt a lump in her left breast. A fine needle aspiration was performed but was nondiagnostic. Mammogram revealed only a 1-cm abnormality despite a large palpable mass. Multiple stereotactic needle biopsies were then performed, and biopsy was positive for multicentric versus extensive malignancy.
The patient underwent a left modified radical mastectomy and axillary node dissection. The tumor was found to be 5.5 cm in size. Pathology revealed lobular carcinoma. Tumor was estrogen-receptor (ER) positive (90%) and progesterone-receptor (PR) negative (5%). The tumor extended to within 2 mm of the deep margin of resection. Sixteen out of 17 lymph nodes were positive for metastatic disease. The tumor was diploid with an S phase of 17.4%, nuclear grade 2-3 with moderate mitotic index. Other areas of lobular carcinoma were also found in situ in the surgical specimen. Staging workup was performed and was negative. The patient, hence, had T3, N2, MO disease/ stage IIIA. She received adjuvant chemotherapy with Adriamycin and Cytoxan for 6 cycles. Her treatment was started in December of 1995 and was completed in March of 1996. She was then started on tamoxifen 10 mg twice a day. She also received adjuvant radiation treatment. She continued to have regular follow-ups and was doing well until March of 1999 when the tumor marker (CA 27, 29) increased. The patient also complained of left hip/greater trochanter tenderness and pain which occasionally woke her up at night. This pain was not exacerbated with weight bearing. Bone scan revealed increased uptake in the L2 vertebral body and intertrochanteric region of the left femur, new when compared to the bone scan from 1995. CA 27,29 levels continued to be monitored, and it doubled in less than 6 months, absolute value of 189. The patient was started on letrozole, and this was discontinued in February of 2000 partially because she did not tolerate this medication well. Follow-up in May of 2000 revealed significant increase in the CA 27,29 level, and at this point the patient was started on Aromasyn 25 mg (another aromatase inhibitor), but she did not initiate this medication until August. She followed up with her oncologist in August of 2000. At that time she was complaining of skeletal pain. The pain was primarily in the peripelvic region, sometimes involving both iliac crests and occasionally in the left groin. MRI scan of the pelvis revealed abnormal signal intensity that was symmetric. Because of the symmetric distribution, metastatic disease was discounted. Bone marrow aspiration and biopsy were recommended, but the patient resisted this. It was at this point in August that she decided to start on the Aromasyn. In September of 2000, she had a repeat bone scan that revealed progression of disease with increased uptake noted in the femur, clavicle, rib, and sacrum. CA 27,29 at this time was found to be significantly elevated at 1822. The patient was started on Aredia treatment in October of 2000. She was then seen in our clinic at the Block Center for Integrative Cancer Care (BCICC).
Advanced Breast Cancer
Past medical history:
Hypothyroidism; breast carcinoma diagnosed in 1995, and metastatic disease diagnosed in 1999.
Past surgical history: Appendectomy at age 8; Cesarean section in 1978; left modified radical mastectomy with axillary node dissection in 1995.
Medications: Armour Thyroid 15 gr, Vioxx 25 mg qd. Coumadin 1 mg qod, Aredia 90 mg q monthly.
Allergies: No known drug allergies, but patient is allergic to surgical tape.
Family history: Positive for breast carcinoma in an aunt and niece who were premenopausal at time of the diagnosis. Three sisters, alive and well. She currently eats almost all meals at home, mostly in front of the TV. She tends to crave sweets but sometimes also craves salty foods. Patient uses an electric stove for cooking. Patient rarely experiences any hunger and has noticed a significant decrease in appetite.
One-day diet (before integrated nutrition intervention): Breakfast: Yogurt and green drink with figs. Lunch: Salad with seaweed and cabbage. Dinner: Brown rice with miso, broccoli, onions, raw radishes, raw beet juice with carrots, greens, vitamin C, and desiccated liver. She usually snacks on apples and beverages of water and green tea. Ninety-percent of meals are eaten at home and 10% are eaten in restaurants. About 50%-60% of food eaten is raw and 40% is cooked.
Exercise history:
The patient is less capable of exercising now because her activities are very limited because of pain and fatigue. She loves to walk and garden and used to be physically active. She still tries to lift weights and walk and garden on a daily basis. However, she can no longer run, jog, dance, or swim.
Musculoskeletal issues:
The patient complains of significant bony pain that is generalized but more intense in the pelvic area.
Supplement history:
At the time the patient entered our facility she was taking the following supplements: Multivitamins; Ester C, Digase, mixed carotene, E400, Primal Defense G-132, Bone Guardian, selenium, lipoic acid, coenzyme Q10, IP6 Cell Forte, Transfer Factor Plus, silymarin, isoflavone-ipriflavone, Indolplex, and Quercetin Plus.
Emotional stress factors:
The patient characterizes herself as an optimistic person: maintains a positive attitude, is warm, affectionate and honest with other people. Priorities in life include (1) associationsrelationships, (2) vitality and performance, (3) libido, (4) solace (freedom from pain), (5) longevity, (6) security, and (7) recognition-acknowledgment for work. She has a demanding home-based business and financial concerns.
The patient is Catholic; attended Catholic schools while growing up.
Physical examination:
The patient is a well-developed, pleasant female, alert, and in no acute distress. Patient had an oxidative panel performed in 3/01 after 3 months of integrative intervention. Vitamin A was high at 4.45, gamma tocopherol normal at 0.94, alpha tocopherol normal at 28.29, beta-carotene high at 4.04, alpha-carotene high at 0.67, ascorbic acid normal at 0.38, coenzyme Q 10 high at 2.05. Total oxidative protection index high normal at 62%. Lycopene normal at 0.68, lutein normal at 0.43. Immune panel revealed normal natural killer cell function of 72%. Total white blood cell count high at 21,600, total lymphocytes normal at 2700. Percentage of CD3+ (T cells) low at 58%, number of CD3+ (T cells) normal at 1566, percentage of CD4+ (T helper cells) low at 29%, number of CD4+ (T helper cells) 783, percentage of CD8+ (T suppressor cells) 30%, number of CD8+ (T suppressor cells) 810. CD4 to CD8 ratio is 0.96.
Marital/home issues:
Has a wonderful marriage of 25 years; her husband is loving, affectionate, and hardworking. Her family is loving, caring, and supportive. year after first round of chemotherapy. Lubricating gels do not help.
Current symptoms/date started:
Life Patterns
The patient is the oldest of 6 children. She had long hospitalizations with her appendectomy as a child. She has worked in a dentist's office. She now has a home-based business that causes some stress due to difficulty of keeping up with accounting. She would like to change her attitudes about money, which she characterizes as negative. She likes to garden (now difficult due to her medical condition) and to walk in nature, and is learning watercolor painting. She likes change, regards herself as flexible and an explorer. She has been using tapes for the immune system and breathing techniques for stress.
Sleep Patterns
She typically gets 6 to 8 hours sleep and is awakened by the sun. She sometimes has trouble getting to sleep after late suppers and does not have much of a routine.
Recent Stressful Life Events (past 3 years) These have included illness, financial change/ concerns, death of close friend, personal achieivement, work changes, mortgage concern.
Traditional Chinese Medicine Diagnostics Systemic: fatigue since 5/2000 (anemia, still somewhat fatigued); always cold to the bone (before chemotherapy), warm during chemotherapy treatments; lack of perspiration for the last 3 years, even during hot weather.
Respiratory: difficulty inhaling
Intake: excessive thirst (last 2 years); drinks a lot; prefers room temperature or warm drinks; poor appetite.
Outflow: chronic sinus problems; frequent, profuse urination; chemo gives her loose, watery stools; has used daily coffee enemas for the last several years; fingertips crack and bleed after chemo; occasional nosebleeds; menstrual history: last period in 12/1995 due to chemotherapy.
Pain: dry skin and eyes; bruises easily; hip pain due to tumor.
Sensation: dizziness (due to anemia).
Sleep: 6 to 8 hours; remembers no dreams; difficulty falling and staying asleep; restless sleep; chills at night.
Speech: low, soft and slow
Behavior: trouble in making decisions; sometimes easily angered. 
Medical Oncology Analysis
Lobular carcinoma of the breast represents approximately 5% to 10% of breast cancers. Lobular carcinoma can often present as a very large tumor whose size is underestimated by the physical examination and the mammographic findings. 1 The small mammographic abnormality (1 cm) with a large palpable mass seen in this patient is not uncharacteristic for lobular carcinoma.
The large primary tumor (greater than 5 cm) makes the patient a candidate for consideration of neo-adjuvant chemotherapy prior to her surgical procedure. Neo-adjuvant chemotherapy would allow an in vivo assessment of the tumor's sensitivity to the chemotherapy. If primary resistance to the Adriamycin/ Cytoxan combination was observed then an alternative treatment with a taxane alone or in combination with another chemotherapeutic agent could have been used after surgery in the adjuvant setting. In addition, successful neo-adjuvant treatment would have reduced the size of primary tumor and the degree of axillary node involvement allowing for more effective surgical removal of disease and making breast conservation feasible for such large tumors. With neo-adjuvant therapy, any micrometastatic systemic tumor may also be decreased. This impairs the formation of resistant cellular clones and the response to angiogenesis and other serum growth factors that are formed after the removal of the primary malignancy. 2 In spite of the potential benefits of neoadjuvant chemotherapy, no survival advantage has been demonstrated in multiple randomized clinical trials. A survival benefit however has been seen in those patients who have been able to achieve a pathologic complete remission documented at the time of surgery. 2 The patient at the surgery was noted to have multiple adverse prognostic features. The primary tumor was greater than 5 cm in diameter (stage III) with involvement of 16 out of 17 axillary lymph nodes suggesting a high probability of metastatic disease and an estimated 5-year survival of less than 50%. 1 At a number
